YU44801B - Process for obtaining benzolsulphonate salt of 3-ethyl-5-methyl-2-(2-aminoetoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl pyridin-3,5-dicarboxylate - Google Patents

Process for obtaining benzolsulphonate salt of 3-ethyl-5-methyl-2-(2-aminoetoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl pyridin-3,5-dicarboxylate

Info

Publication number
YU44801B
YU44801B YU580/87A YU58087A YU44801B YU 44801 B YU44801 B YU 44801B YU 580/87 A YU580/87 A YU 580/87A YU 58087 A YU58087 A YU 58087A YU 44801 B YU44801 B YU 44801B
Authority
YU
Yugoslavia
Prior art keywords
methyl
benzolsulphonate
aminoetoxymethyl
dicarboxylate
chlorophenyl
Prior art date
Application number
YU580/87A
Other languages
English (en)
Other versions
YU58087A (en
Inventor
E Davison
J I Wells
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU44801(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Priority to SI8710580A priority Critical patent/SI8710580A8/sl
Publication of YU58087A publication Critical patent/YU58087A/xx
Publication of YU44801B publication Critical patent/YU44801B/xx
Priority to HR950452A priority patent/HRP950452B1/xx
Priority to BA970148A priority patent/BA97148B1/bs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
YU580/87A 1986-04-04 1987-04-02 Process for obtaining benzolsulphonate salt of 3-ethyl-5-methyl-2-(2-aminoetoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl pyridin-3,5-dicarboxylate YU44801B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI8710580A SI8710580A8 (sl) 1986-04-04 1987-04-02 Postopek za pridobivanje benzolsulfonatne soli 3-etil-5-metil-2-(2-aminoetoksimetil)- 4-{2-klorofenil)-1.4-dihidro-6- metilpiridin-3.5-dikarboksilata
HR950452A HRP950452B1 (en) 1986-04-04 1995-08-16 Process for the preparation of benzosulphonate salts 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)1,4-dihydro-6-methylpyridine -3,5-dicarboxylate
BA970148A BA97148B1 (bs) 1986-04-04 1997-03-28 Postupak za dobivanje benzolsulfonatne soli 3-etil-5-metil-2-(aminoetoksimetil)-4-(2-klorofenil) 1,4-dihidro-6-metilpiridin-3,5-dikarboksilata

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts

Publications (2)

Publication Number Publication Date
YU58087A YU58087A (en) 1988-08-31
YU44801B true YU44801B (en) 1991-02-28

Family

ID=10595731

Family Applications (1)

Application Number Title Priority Date Filing Date
YU580/87A YU44801B (en) 1986-04-04 1987-04-02 Process for obtaining benzolsulphonate salt of 3-ethyl-5-methyl-2-(2-aminoetoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl pyridin-3,5-dicarboxylate

Country Status (47)

Country Link
US (1) US4879303A (OSRAM)
EP (1) EP0244944B1 (OSRAM)
JP (1) JPS62240660A (OSRAM)
KR (1) KR950006710B1 (OSRAM)
CN (1) CN1023800C (OSRAM)
AP (1) AP50A (OSRAM)
AR (1) AR242562A1 (OSRAM)
AT (1) ATE49752T1 (OSRAM)
BE (1) BE1000130A4 (OSRAM)
BG (1) BG60698B2 (OSRAM)
CA (1) CA1321393C (OSRAM)
CS (1) CS265237B2 (OSRAM)
CY (1) CY1669A (OSRAM)
CZ (1) CZ289095B6 (OSRAM)
DD (1) DD265142A5 (OSRAM)
DE (2) DE3710457A1 (OSRAM)
DK (1) DK171708B1 (OSRAM)
EC (1) ECSP941129A (OSRAM)
EG (1) EG18266A (OSRAM)
ES (2) ES2012803B3 (OSRAM)
FI (1) FI85017C (OSRAM)
FR (1) FR2596758B1 (OSRAM)
GB (2) GB8608335D0 (OSRAM)
GR (2) GR870525B (OSRAM)
HK (1) HK76092A (OSRAM)
HU (1) HU196962B (OSRAM)
IE (1) IE59457B1 (OSRAM)
IL (1) IL82101A (OSRAM)
IN (1) IN168414B (OSRAM)
IT (1) IT1203853B (OSRAM)
LU (1) LU86812A1 (OSRAM)
MA (1) MA20938A1 (OSRAM)
MX (1) MX5847A (OSRAM)
MY (1) MY101177A (OSRAM)
NL (1) NL8700791A (OSRAM)
NO (1) NO172181C (OSRAM)
NZ (1) NZ219868A (OSRAM)
PH (1) PH24348A (OSRAM)
PL (1) PL149532B1 (OSRAM)
PT (1) PT84611B (OSRAM)
SE (1) SE463457B (OSRAM)
SG (1) SG59692G (OSRAM)
SK (1) SK278435B6 (OSRAM)
SU (1) SU1498388A3 (OSRAM)
UA (1) UA6344A1 (OSRAM)
YU (1) YU44801B (OSRAM)
ZA (1) ZA872439B (OSRAM)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
CA2124445A1 (en) * 1991-11-26 1993-06-10 James W. Young Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69626958T2 (de) 1995-03-16 2004-03-18 Pfizer Inc. Verwendung von amlodipin, eines seiner salze oder felodipin in kombination mit einem ace-hemmer zur herstellung eines arzneimittels zur behandlung von nicht ischämischer kongestiver herzinsuffizienz
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
WO1999018957A1 (en) * 1998-03-26 1999-04-22 Reddy-Cheminor, Inc. Stable pharmaceutical composition containing amlodipine besylate and atenolol
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
CZ304359B6 (cs) 1998-07-10 2014-03-26 Novartis Ag Farmaceutická kombinační kompozice
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
UA33033A (uk) * 1998-10-16 2001-02-15 Др.Редіс Леборетрис Лтд Спосіб одержання безилату амлодипіну
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
RU2142942C1 (ru) * 1999-04-28 1999-12-20 Дж. Б.Кемикалс энд Фармасьютикалс Лтд. Способ получения монобензолсульфоната 3-этил-5-метилового эфира 2-[(2-аминоэтокси)метил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5-пиридинди карбоновой кислоты
JP2003500487A (ja) 1999-05-27 2003-01-07 ファイザー・プロダクツ・インク アムロジピンおよびアトルバスタチンの共通プロドラッグ
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
RU2161156C1 (ru) * 1999-06-01 2000-12-27 Джи.Б.Кемикалс Энд Фармасьютикалс Лтд Способ получения 3-этил-5-метиловый эфир 2-[2-(n-фталимидо)-этоксиметил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5- пиридиндикарбоновой кислоты
UA72768C2 (en) * 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
RU2146672C1 (ru) * 1999-10-13 2000-03-20 Др.Редди'С Лабораторис Лтд. Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
AU2001283085A1 (en) 2000-08-04 2002-02-18 R. Preston Mason Synergistic effect of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
BR0116554A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
WO2002053539A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amlodipine hemimaleate
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
EP1309555B1 (en) 2000-12-29 2005-07-27 Pfizer Limited Process for making amlodipine maleate
CA2433191A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Aspartate derivative of amlodipine as calcium channel antagonist
WO2002054062A2 (en) 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
DE50112189D1 (de) * 2001-01-09 2007-04-26 Siegfried Generics Int Ag Salze von Amlodipin-Mesylat
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
ATE454890T1 (de) 2001-07-06 2010-01-15 Lek Pharmaceuticals Verfahren zur herstellung hochreines amlodipinbenzolsulfonat
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US6828339B2 (en) * 2001-11-21 2004-12-07 Synthon Bv Amlodipine salt forms and processes for preparing them
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP1499592A4 (en) * 2002-04-13 2010-01-13 Hanlim Pharmaceutical Co Ltd AMLODIPINE NICOTINATE AND PROCESS FOR PREPARING THE SAME
EP2151250B1 (en) 2002-05-06 2013-10-02 Endocyte, Inc. Vitamin-Targeted imaging agents
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
RU2221784C1 (ru) * 2002-07-05 2004-01-20 Марвел Лайфсайнсез Прайвит Лимитед Способ получения бензолсульфоната амлодипина
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) * 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
ZA200501418B (en) 2002-08-29 2006-10-25 Taisho Pharmaceutical Co Ltd Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
WO2004024690A1 (en) * 2002-09-11 2004-03-25 Hanlim Pharmaceutical Co., Ltd. S-(-)-amlodipine nicotinate and process for the preparation thereof
WO2004026834A1 (en) * 2002-09-19 2004-04-01 Cj Corporation Crystalline organic acid salt of amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (en) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research A process for the preparation of s (-) amlodipine salts
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
AU2002368531A1 (en) * 2002-12-30 2004-07-22 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
BRPI0407038A (pt) 2003-01-27 2006-01-17 Hanmi Pharm Ind Co Ltd Camsilato de amlodipina amorfo estável, processo para a preparação do mesmo e composição para administração oral deste
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
WO2004075825A2 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Dosage forms of amlodipine and processes for their preparation
WO2004096770A1 (en) * 2003-04-25 2004-11-11 Cipla Limited Process for preparing almodipine mesylate monohydrate
EP1927595B1 (en) 2003-04-25 2013-03-06 Cadila Healthcare Limited Salts of clopidogrel and process for preparation
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
EP1636183A1 (en) * 2003-05-16 2006-03-22 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
KR20110117731A (ko) 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
RU2239433C1 (ru) * 2003-06-09 2004-11-10 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая вазодилатирующим, антиангинальным, гипотензивным и спазмолитическим действием, и способ ее изготовления
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
KR100841409B1 (ko) 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030602A1 (en) * 2004-03-16 2006-02-09 Sepracor Inc. (S)-amlodipine malate
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005279961B2 (en) * 2004-08-30 2010-05-13 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
EP1809330B1 (en) * 2004-10-15 2011-04-27 Seo Hong Yoo Compositions for reducing toxicity of cisplatin, carboplatin, and oxaliplatin
ATE491456T1 (de) * 2004-11-01 2011-01-15 Seo Hong Yoo Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
CA2610838A1 (en) * 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
CA2613417C (en) * 2005-06-27 2011-11-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE602005005706T2 (de) * 2005-09-28 2009-04-16 Teva Pharmaceutical Industries Ltd. Stabile Arzneimittelkombinationen von Amlodipinbesylat und Benazeprilhydrochlorid
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
US8377990B2 (en) 2006-07-17 2013-02-19 Ramot At Tel-Aviv University Ltd. Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
JP2011502953A (ja) * 2006-12-21 2011-01-27 ゼノポート，インコーポレーテッド ジメチル置換されたレボドパジエステルのプロドラッグ、組成物及び使用方法
CN105152983A (zh) 2007-01-29 2015-12-16 韩诺生物制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US8748648B2 (en) 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
EP2203418B1 (en) * 2007-09-21 2017-10-25 HanAll Biopharma Co., Ltd. N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
EP2240163A1 (en) 2007-12-31 2010-10-20 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
RU2359672C1 (ru) * 2008-02-18 2009-06-27 Зао "Биоком" Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349973A2 (en) * 2008-10-20 2011-08-03 XenoPort, Inc. Methods of synthesizing a levodopa ester prodrug
WO2010070705A1 (ja) * 2008-12-17 2010-06-24 株式会社メドレックス アムロジピンの安定な含水経口製剤
UA102721C2 (uk) 2009-01-23 2013-08-12 Ханми Сайенс Ко., Лтд. Тверда фармацевтична композиція, яка містить амлодипін і лозартан, і спосіб її отримання
AU2010315892B2 (en) * 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CA2782514A1 (en) 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
JP5745283B2 (ja) 2010-02-12 2015-07-08 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
CN102858345A (zh) 2010-02-24 2013-01-02 雷蒙特亚特特拉维夫大学有限公司 奋乃静-gaba的三甲磺酸盐的晶型及其制备方法
WO2011117876A1 (en) 2010-03-26 2011-09-29 Fdc Limited An improved process for the preparation of amlodipine free base and acid addition salts thereof
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
BR112013003388A2 (pt) * 2010-08-10 2016-07-12 Celgene Avilomics Res Inc sal de besilato de um inibidor de btk
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
NZ609957A (en) 2010-11-01 2015-08-28 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
WO2012071524A1 (en) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
CN109053595B (zh) 2012-03-15 2022-04-01 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的盐
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US20150374713A1 (en) 2013-02-08 2015-12-31 Wockhardt Limited Stable pharmeceutical composition of amlodipine and benazepril or salts thereof
HK1213886A1 (zh) 2013-04-17 2016-07-15 辉瑞大药厂 用於治療心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
WO2017030893A1 (en) 2015-08-14 2017-02-23 Endocyte, Inc. Method of imaging with a chelating compound
WO2017068532A1 (en) 2015-10-23 2017-04-27 Ftf Pharma Private Limited Oral solution of dihydropyridine derivatives
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (en) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
EP3463309B1 (en) 2016-05-30 2020-06-17 Boehringer Ingelheim International GmbH Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
EP3960158B1 (en) 2016-10-07 2025-05-21 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
CA3096101A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN112955965B (zh) 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
PH12021551686A1 (en) 2019-01-18 2022-05-16 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
WO2023285646A1 (en) 2021-07-15 2023-01-19 Adamed Pharma S.A A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
SK278435B6 (en) 1997-05-07
HK76092A (en) 1992-10-09
IT1203853B (it) 1989-02-23
HU196962B (en) 1989-02-28
ATE49752T1 (de) 1990-02-15
FR2596758B1 (fr) 1988-12-02
GB8608335D0 (en) 1986-05-08
EP0244944A2 (en) 1987-11-11
CN87102493A (zh) 1987-10-14
SE8701348L (sv) 1987-10-05
ECSP941129A (es) 1994-12-15
AR242562A1 (es) 1993-04-30
EP0244944A3 (en) 1988-01-07
PT84611B (pt) 1989-11-30
SE463457B (sv) 1990-11-26
ZA872439B (en) 1988-11-30
NZ219868A (en) 1989-02-24
MX5847A (es) 1993-08-01
NO871408L (no) 1987-10-05
PT84611A (en) 1987-05-01
BE1000130A4 (fr) 1988-04-12
JPH037668B2 (OSRAM) 1991-02-04
MA20938A1 (fr) 1987-12-31
GB2188630A (en) 1987-10-07
DK170187A (da) 1987-10-05
NL8700791A (nl) 1987-11-02
SE8701348D0 (sv) 1987-03-31
EP0244944B1 (en) 1990-01-24
CY1669A (en) 1993-05-14
JPS62240660A (ja) 1987-10-21
CS236387A2 (en) 1989-01-12
DD265142A5 (de) 1989-02-22
IE870869L (en) 1987-10-04
DK170187D0 (da) 1987-04-03
ES2012803B3 (es) 1990-04-16
IT8719977A0 (it) 1987-04-03
PL264982A1 (en) 1988-05-26
IL82101A0 (en) 1987-10-30
KR870009998A (ko) 1987-11-30
YU58087A (en) 1988-08-31
DE3710457A1 (de) 1987-10-08
CZ289095B6 (cs) 2001-10-17
FI85017C (fi) 1992-02-25
SU1498388A3 (ru) 1989-07-30
UA6344A1 (uk) 1994-12-29
NO871408D0 (no) 1987-04-03
CS265237B2 (en) 1989-10-13
EG18266A (en) 1992-12-30
DE3761485D1 (de) 1990-03-01
AU7103087A (en) 1987-10-08
PL149532B1 (en) 1990-02-28
IL82101A (en) 1991-01-31
GB8707653D0 (en) 1987-05-07
PH24348A (en) 1990-06-13
MY101177A (en) 1991-07-31
DK171708B1 (da) 1997-04-01
FR2596758A1 (fr) 1987-10-09
CS353991A3 (en) 1992-04-15
KR950006710B1 (ko) 1995-06-21
AU573123B2 (en) 1988-05-26
GR870525B (en) 1987-08-12
GR3000394T3 (en) 1991-06-07
FI871470A0 (fi) 1987-04-03
FI85017B (fi) 1991-11-15
ES2002599A6 (es) 1988-08-16
HUT43821A (en) 1987-12-28
CA1321393C (en) 1993-08-17
AP50A (en) 1989-09-16
IN168414B (OSRAM) 1991-03-30
CN1023800C (zh) 1994-02-16
GB2188630B (en) 1990-04-04
IE59457B1 (en) 1994-02-23
NO172181C (no) 1993-06-16
LU86812A1 (fr) 1987-08-12
US4879303A (en) 1989-11-07
SG59692G (en) 1992-12-04
AP8700060A0 (en) 1987-02-01
FI871470L (fi) 1987-10-05
NO172181B (no) 1993-03-08
BG60698B2 (en) 1995-12-29

Similar Documents

Publication Publication Date Title
YU44801B (en) Process for obtaining benzolsulphonate salt of 3-ethyl-5-methyl-2-(2-aminoetoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl pyridin-3,5-dicarboxylate
GB2164336B (en) 4-aryl-1,4-dihydropyridine-3,5-dicarboxylate derivatives
FI882001A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 2-(2-aminoetoksimetyyli)-4-(2-kloorifenyyli)-3-etoksikarbonyyli-5-metoksikarbonyyli-6-metyyli-1,4-dihydropyridiinien valmistamiseksi
PL252773A1 (en) Method of obtaining novel derivatives of 1,4-dihydropyridine
YU182088A (en) Process for obtaining derivatives of 4-aryl-5-carbamoyl-1,4-dihydropyridine
EP0234776A3 (en) Process for 1,4-dihydropyridine compounds
YU201987A (en) Process for obtaining dihydropyridine
PT85075A (en) Process for preparing antihypertensive dihydropyridine derivatives
PL253821A1 (en) Method of obtaining derivatives of 1,4-dihydropyridine
PT84959A (en) Process for the preparation of novel 1,4-dihydropyridines
PL253820A1 (en) Method of obtaining derivatives of 1,4-dihydropyridine
HUT37755A (en) Process for preparing dihydropyridine derivatives
HRP950452B1 (en) Process for the preparation of benzosulphonate salts 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)1,4-dihydro-6-methylpyridine -3,5-dicarboxylate
HUT40412A (en) Process for preparing dihydropyridine derivatives
HUT40415A (en) Process for producing dihydropyridine derivatives
YU228987A (en) Process for obtaining compounds of 5-t-buthyl-3-(4-chloro-2-fluoro-5-propargylotoskiphenyl)-1,3,4-oxadiazol-2-ones
AU557521B2 (en) 3-(2-fruoyl)-5-alkoxy-2,6-dimethyl-4-(2-nitrophenyl)- 1,4-dihydropyridine
PL271920A1 (en) Method for manufacturing new derivatives of 1,4 - dihydropyridine
YU44951B (en) Process for preparing isopropyl 2-metoxyethyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridin 3,5-dicarboxylate
YU44586B (en) Process for preparing ethyl methyl-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylate
YU66687A (en) Process for obtaining hydrochloride of 2(n-benzyl-n-m-ethylamino)-ethyl-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridin-dicarboxilate
IL94502A0 (en) Preparation of methyl,1,2-dihydroxypropan-3-yl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate
PL256694A1 (en) Method of obtaining derivatives of 1,4-dihydropyridine
HUT40411A (en) Process for producing dihydropyridine derivatives
GB2180532B (en) Alkoxy-and phenoxy-alkyl-esters of 2,6-dimethyl-4-(2-difluoromethoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid